The Phase 2 clinical trial of ALGRX 4975 is showing positive results according to Corgentech Inc. ALGRX 4975 is one of three non-opioid pain management drug candidates the company is developing for pain relief of patients with elbow tendonitis.
Corgentech Inc. President James Z. Huang is confident that ALGRX 4975 has demonstrated its ability to provide pain relief to patients experiencing post-surgical, neuropathic and musculoskeletal pain for weeks to months after only a single administration.
Read the full press release.
.jpg)
Comment Preview